Novo Nordisk is investing 8.5 billion Danish kroner ($1.2 billion) to establish a new production facility in Odense, Denmark—marking the first time in this century that Novo Nordisk will break ground in Denmark by establishing a new production site. 
 
The new site will feature a finished production facility and warehouse spanning over 40,000 m². Designed to be modular and flexible, it will accommodate multiple product types within rare disease.  
 
“The facility will utilize advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines,” says Henrik Wulff, executive vice president, Product Supply, Quality & IT of Novo Nordisk. “We are proud to build on our heritage in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and talented workforce.”
 
The new facility will be established with a commitment to preserve nature in the area, and more than 4,000 new trees will be planted at the site. Buildings will be equipped with solar panels to enhance on-site electricity generation. The landscape will be designed by reusing excess soil, wooden materials and other sustainable resources to create lakes, forests and community spaces open to the public.
 
Construction work has commenced and is scheduled to be completed in 2027. The investment is expected to create 400 permanent jobs upon completion of the facilities. During the construction process, up to 1,000 external employees will be working on-site.

Related News